Profile data is unavailable for this security.
About the company
Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. It has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The Company conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.
- Revenue in AUD (TTM)337.51k
- Net income in AUD-14.87m
- Incorporated1999
- Employees--
- LocationActinogen Medical LtdSelect HouseSE 901 L 9, 109 Pitt StreetSYDNEY 2000AustraliaAUS
- Phone+61 28964-7401
- Fax+61 28964-7588
- Websitehttps://actinogen.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vimta Labs Ltd | 56.96m | 7.39m | 212.97m | 1.43k | 29.14 | -- | 15.78 | 3.74 | 18.32 | 18.32 | 141.14 | -- | -- | -- | -- | 2,216,604.00 | -- | 10.53 | -- | 12.77 | 76.48 | 73.65 | 12.98 | 12.16 | -- | 26.56 | -- | 5.58 | 0.0223 | 8.40 | -14.87 | 10.13 | 35.88 | 0.00 |
Actinogen Medical Ltd | 337.51k | -14.87m | 242.51m | -- | -- | 17.58 | -- | 718.52 | -0.0073 | -0.0073 | 0.0002 | 0.0051 | 0.0211 | -- | 0.7341 | -- | -92.99 | -45.55 | -105.88 | -48.24 | -- | -- | -4,405.86 | -5,369.76 | -- | -294.93 | 0.0037 | -- | 792.74 | 31.88 | -13.21 | -- | 166.95 | -- |
Chordia Therapeutics Inc | -958.69m | -958.69m | 268.29m | 21.00 | -- | 7.05 | -- | -- | -- | -- | -- | 58.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 112.55 | -- | -- | -- |
Jacobio Pharmaceuticals Group Co Ltd | 13.16m | -74.39m | 269.06m | 301.00 | -- | 1.21 | -- | 20.45 | -0.4991 | -0.4991 | 0.0883 | 1.46 | 0.0419 | -- | 5.21 | 226,723.30 | -23.66 | -45.76 | -26.86 | -49.30 | 5.04 | -- | -565.36 | -372.22 | -- | -- | 0.1636 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 14 May 2024 | 247.33m | 9.97% |
SSgA Funds Management, Inc.as of 03 Jul 2024 | 11.24k | 0.00% |